Company News

A recent study highlights the efficacy and safety of NS7CAR-T cell therapy in treating relapsed or refractory T-cell acute lymphoblastic leukemia (R/R T-ALL) and T-cell lymphoblastic lymphoma (R/R T-LBL). This therapy offers new hope for patients with these aggressive forms of cancer.

The 12th Annual Lu Daopei Hematology Forum is set to take place on August 23-24, 2024, at the Beijing International Convention Center. Join us for insightful discussions and the latest advancements in hematology.

A phase I clinical study of CD7 CAR-T for R/R AML by Daopei Lu's team debuts at ASHThe 65th Annual Meeting of the American Society of Hematology (ASH) was held offline (San Diego, USA) and online on December 9-12, 2023.Our scholars made a great show of this co...

The American Society of Hematology (ASH) is the top academic meeting in the field of haematology worldwide. The fact that Lu Daopei Hospital has been selected as a finalist for the ASH for consecutive years fully demonstrates its academic achievements in the f...